Meeting
2018 ASCO Annual Meeting
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
Authors
Toshimi Takano
Toranomon Hospital, Tokyo, Japan
Toshimi Takano , Chiyo K. Imamura , Kenji Tamura , Shigehira Saji , Takeharu Yamanaka , Kan Yonemori , Masato Takahashi , Junji Tsurutani , Reiki Nishimura , Kazuhiko Sato , Akira Kitani , Naoto T. Ueno , Taisei Mushiroda , Michiaki Kubo , Yasuhiro Fujiwara , Yusuke Tanigawara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
UMIN000009155
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1046)
DOI
10.1200/JCO.2018.36.15_suppl.1046
Abstract #
1046
Poster Bd #
127
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.
First Author: Vered Stearns
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2020 ASCO Virtual Scientific Program
Relationship between CYP2D6 genotype, tamoxifen metabolites, and adverse events, tumor biomarkers and breast cancer recurrence in a low-dose phase III trial in noninvasive disease.
First Author: Andrea De Censi
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan